Mantle Cell Lymphoma

Adding Calquence to standard-of-care chemoimmunotherapy improved progression-free survival in patients with previously untreated mantle cell lymphoma.

A CAR NK therapy made from cord blood showed promising responses in patients with relapsed or refractory B-cell malignancies.

Patients with relapsed/refractory mantle cell lymphoma described by one expert as “older, sicker and more heavily pretreated” than those previously studied experienced impressive responses to treatment with CAR-T cell therapy Tecartus.

Tecartus is safe and effective in real-world patients with relapsed/refractory mantle cell lymphoma, regardless of the presence of high-risk features.

Breyanzi has reportedly shown promising effects for patients with relapsed or refractory follicular lymphoma and B-cell non-Hodgkin lymphoma.

Long-term data showed that the addition of Imbruvica did not improve overall survival in patients with marginal zone lymphoma or mantle cell lymphoma.

Here’s a look back at the cancer drugs that gained FDA approval in the winter of 2023.

An expert discusses the value of Jaypirca’s recent accelerated FDA approval for relapsed/refractory mantle cell lymphoma, as well as where treatment may go next.

The Food and Drug Administration approved Jaypirca for patients with relapsed/refractory mantle cell lymphoma who have been previously treated with multiple lines of therapy.

We need to learn more about how to potentially lessen toxins' effects on people's lives.

Long-term follow-up shows that the CAR-T cell therapy Tecartus continues to elicit durable responses in patients with relapsed/refractory mantle cell lymphoma.

Adding Imbruvica to a standard-of-care chemotherapy-immunotherapy treatment regimen was associated with a significant improvement in survival in older patients with newly diagnosed mantle cell lymphoma.

NX-5948 may be able to pass through the blood-brain barrier in patients with B-cell malignancies, potentially making it a promising option for patients with disease in their central nervous system.

Dying does not have the be scary, and there are resources available to help patients and their loved ones, explained an expert.

The use of bendamustine and Rituxan plus autologous stem cell transplantation and maintenance Rituxan resulted in similar outcomes to other Rituxan-based regimens that are currently the standard of care for young patients with mantle cell lymphoma, a type of non-Hodgkin lymphoma, who are eligible for transplant.

The plan, according to the San Diego-based pharmaceutical company, is to launch a phase 3 trial to analyze the safety and efficacy of a novel drug in mantle cell lymphoma in the second half of 2022.

The COVID-19 pandemic brought on a huge surge in the use of telemedicine for cancer care, but now as the pandemic is slowing down, an expert said that there are certain times when telemedicine will do, while other situations warrant an in-person visit with the doctor.

CAR-T cell therapies offer patients with lymphoma a chance for long-term remission, but none have yet to receive a greenlight from the FDA as a first line of treatment.

Treatment with ofatumumab plus an aggressive regimen of chemotherapies resulted in a response rate of more than 80% in patients with newly diagnosed mantle cell lymphoma.

Treatment with TRPH-222 led to lasting responses in certain patients with relapsed/refractory B-cell non-Hodgkin lymphomas, warranting a larger investigation into the drug, according to the researchers.

In the midst of my treatment for mantle cell lymphoma, I had to suffer through the feeling of wanting to crawl out of my own skin when my oncologist gave me a medication tapering plan that was not gradual enough.

From the use of BTK inhibitors to maintenance therapy, an expert highlights how the treatment landscape of mantle cell lymphoma has drastically changed for the better in recent decades.

Supportive care should be implemented promptly after patients receive CAR-T cell therapy, but as one expert notes, patients with cancer are often referred for this care too late.

A phase 3 trial evaluating the safety and efficacy of the BTK inhibitor LOXO-305 in patients with previously treated mantle cell lymphoma is now open to patients across more than a dozen states.

The National Comprehensive Cancer Network now recommends prophylactic monoclonal antibodies for immunosuppressed individuals, such as certain patients with cancer.

New findings show that 43% of patients with certain blood cancers produced COVID-19 antibodies after receiving a third full dose of the mRNA vaccine.

With three BTK inhibitors approved for treatment of mantle cell lymphoma, patients and providers should consider side effects and insurance coverage before deciding on a drug.

The Food and Drug Administration will review parsaclisib for the treatment of patients with follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma.

More selective BTK inhibitors like Brukinsa may give patients with mantle cell lymphoma who progressed on prior therapies another option with potentially fewer and more manageable side effects.

After determining an aggressive or non-aggressive treatment approach to mantle cell lymphoma, patients and clinicians must then discuss COVID-19 vaccine efficacy when determining a maintenance treatment strategy.